Cancer Clinical Trials That Help Patients Most Are Losing Funding — Here's Why
If you follow this channel, you know we don't just cover the big pharma blockbusters. We cover small clinical trials from university departments and independent hospitals. We cover trials that compare drugs against each other, combine generics, or look at repurposing existing drugs for cancer. That kind of research — the kind that directly serves cancer patients — is in serious danger right now. And there's something you can do about it before July 13th.
Why Small Clinical Trials Depend on NIH Funding
Pharmaceutical companies fund drug development for their own drugs. That's it. They are not going to fund a trial comparing their drug to a competitor's. They are not going to fund research on a generic drug. They are not going to fund metabolic cancer research or drug repurposing. They will not fund most of the clinical trials you or I would like to see done.
That means any clinical trial outside of getting a new drug to market — the kind that generates the data we discuss here — requires grant funding. NIH funding. Because universities don't have millions of dollars sitting around for a five to ten year trial. Hospitals don't either. Without grants, that research simply doesn't happen.
What the OMB Rules Change Would Actually Mean for Cancer Research
The Office of Management and Budget (OMB) is pushing through a rules change that would allow awarded grants to be pulled at any time, for any reason, with no warning or appeal, and no guarantee of continuation.
Think about what that means for a five year clinical trial. Salaries, patient follow-up, data collection, publication — all of it dependent on long-term funding that could now disappear mid-study. No completed trial means no published data. No published data means cancer patients and cancer doctors never find out whether that approach works.
This isn't a political argument. It's a practical one. Long term financial commitments to cancer research would become meaningless overnight. The chilling effect on biomedical research and drug development would play out over the next five to ten years — even if the rules change is eventually reversed the impact for the next decade would be devastating.
What You Can Do Before July 13th
There is a concrete action available to every cancer patient, caregiver, and person who has ever been touched by cancer. Write a letter. That's it, it is that simple.
A template and mailing instructions are linked in the video description, courtesy of Elizabeth Ginexi's Substack newsletter and Your Local Epidemiologist. The key is to personalize it — write about what this means to you, your family, your treatment options. Form letters will be counted together as a single response. Individual personalized letters are each counted separately. Your letter counts as your voice.
The deadline is July 13th. It must be postmarked by then.
If large pharmaceutical companies become the only entities that can fund cancer research, the treatments that get studied will only be the ones that make money — not the ones that help cancer patients most. That is the world we are heading toward if this passes quietly.
Write that letter.
Accurate science saves lives — and it starts with rejecting simple myths in favor of real understanding. Stay curious.
Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace guidance from your healthcare provider. Cancer and treatment decisions are highly individual—always consult your physician or qualified healthcare professional regarding your specific situation.
A full disclaimer is available Terms and Conditions.